1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

FDA slaps hold on imetelstat studies; Geron whipped

 
• By Donna Young

Investors acted swiftly on 12 March driving shares of Geron down as low as 68.4% after it revealed the FDA had slapped a full clinical hold on the company's Phase II program for its experimental telomerase inhibitor imetelstat (GRN163L) over potential liver injury concerns.

Investors acted swiftly on 12 March driving shares of Geron down as low as 68.4% after it revealed the FDA had slapped a full clinical hold on the company's Phase II program for its experimental telomerase inhibitor imetelstat (GRN163L) over potential liver injury concerns.

Shares of the Menlo Park California-based biotech closed at $1.69, down $2.71, or about 61.6%.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 
• By Andrew McConaghie

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

More from Therapy Areas

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By Manas Mishra

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By Joseph Haas

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.